The Quiet Leverage of a Single Source: A Board Discipline for Concentration Risk

In most American mid-market boardrooms, concentration risk is discussed through the customer lens. Directors ask how much revenue depends on the largest buyer, review contract renewals, and track attrition. Supplier concentration receives less attention, often because procurement presents it as an operating metric rather than an enterprise risk. That omission is costly. A single source for a critical input can be efficient, but it can also become a quiet form of leverage that determines how much room a company has to maneuver when a lender, buyer, or disruption arrives.

Why the Balance Sheet Arrives Late

Supplier concentration seldom appears as a line item. It hides in sole-source agreements, proprietary tooling, qualification cycles, and the simple fact that changing a supplier can take eighteen months and a customer requalification. It sits beneath inventory turns and purchase price variance, invisible until a missed shipment or a renegotiation exposes it. By the time the issue surfaces in diligence or a covenant stress test, the board has fewer options and less time.

That timing problem is a governance problem. Directors do not need to run procurement, but they do need to know where the enterprise is exposed and what decision rights exist when exposure crosses a threshold. Supplier concentration is not merely a purchasing concern. It is a question of operational resilience, margin durability, and ultimately enterprise value.

A Board-Ready Lens: Three Tests

A useful framework begins with three tests. The first is dependency mapping. The board should require a clear view of direct and indirect dependencies: which inputs are sole-sourced, which suppliers sit behind a tier-one vendor, which contracts include change-of-control provisions, and which tooling or intellectual property resides with the supplier. Mapping should include lead times, geographic exposure, and regulatory constraints. A supplier that is replaceable in theory but not in practice remains a single source.

The second test is economic quantification. Directors should ask for revenue at risk, EBITDA at risk, working capital implications, and covenant headroom under a disruption scenario. The exercise should not stop at probability. It should estimate time to recover and the cost of interim mitigation. A supplier failure that affects ten percent of revenue for one quarter is a different governance matter than one that affects forty percent of revenue for six months. The board needs both numbers to make a proportionate decision.

The third test is decision rights. When concentration crosses a defined threshold, who decides whether to diversify, renegotiate, or hedge? Diversification may require capital expenditure and duplicate qualification. Renegotiation may require longer contracts, minimum volumes, or inventory commitments. Hedging may involve financial instruments, buffer stock, or contractual penalties. Each path has a cost, and each should have an owner, a timeline, and a reporting mechanism back to the board.

From Metric to Governance

Concentration risk becomes governable when it is placed on the board agenda with the same discipline as cybersecurity or credit exposure. That means defined limits, quarterly reporting, and a clear escalation path. A risk committee can review concentration dashboards, but the full board should understand the strategic implications. Procurement can own the data; the board owns the tolerance for the risk.

Limits should be practical. A company may accept a sole source where switching costs are prohibitive and contractual protections are strong, but it should do so explicitly rather than by default. The board should also distinguish between concentration that is strategic and concentration that is accidental. A single supplier that supports a differentiated product may be a moat. A single supplier that exists because no one has reviewed the category in five years is an unmanaged exposure.

The Valuation Conversation

Buyers and lenders price concentration, even when sellers do not. A strategic acquirer may discount a business with a fragile supply base, require escrow or earnout protections, or demand a post-closing remediation plan. A lender may tighten covenants, reduce availability, or price in a higher risk premium. The board that addresses concentration before a transaction has more control over the narrative and more room to protect value.

Diversification is rarely free. Dual sourcing can erode scale economics, lengthen qualification timelines, and complicate quality management. But the cost of preemptive action is usually more visible and more manageable than the cost of a crisis. The board's task is not to eliminate concentration. It is to ensure the company is paid for the risk it carries and has a plan to reduce it when the math changes.

When to Act

Not every single source requires immediate action. The board should test whether the supplier is genuinely substitutable, whether contractual protections are enforceable, whether buffer inventory is adequate, and whether the company has a credible second source in development. If those answers are weak, the board should set a trigger and a timetable. If they are strong, the board should document why the risk is acceptable and revisit it on a regular cadence.

Supplier concentration is a governance issue because it affects the choices available to management when conditions change. A board that maps dependencies, quantifies exposure, and assigns decision rights is better prepared for refinancing, succession, and liquidity events. It also sends a clear signal to management that resilience is part of strategy, not an afterthought. The quiet leverage of a single source should never be discovered for the first time in a diligence room.